Journal of Alzheimer’s Disease

2016 Editorial Board Update

Editor-in-Chief
George Perry
impact factor: **3.920** (Web of Science 2015)
- h-index: 77 (Web of Science)
- h-index: 85 (SCImago Journal Rank indicator)
- h5-index of 67 (Google Scholar)
- h5-median of 83 (Google Scholar)

Abstracting/Indexing:
Publishing Schedule: new issue every 2 weeks

2015
- **Volume 43:**
  - Number 1, 2015
  - Number 2, 2015
  - Number 3, 2015
  - Number 4, 2015
- **Volume 44:**
  - Number 1, 2015
  - Number 2, 2015
  - Number 3, 2015 – 200th issue
  - Number 4, 2015
- **Volume 45:**
  - Number 1, 2015
  - Number 2, 2015
  - Number 3, 2015
  - Number 4, 2015
- **Volume 46:**
  - Number 1, 2015
  - Number 2, 2015
  - Number 3, 2015
  - Number 4, 2015
- **Volume 47:**
  - Number 1, 2015
  - Number 2, 2015
  - Number 3, 2015
  - Number 4, 2015
- **Volume 48:**
  - Number 1, 2015
  - Number 2, 2015
  - Number 3, 2015
  - Number 4, 2015
  - Supplement 1, 2015

2016
- **Volume 49:**
  - Number 1, 2016
  - Number 2, 2016 – with Mini-Forum
  - Number 3, 2016
  - Number 4, 2016
- **Volume 50:**
  - Number 1, 2016
  - Number 2, 2016
  - Number 3, 2016
  - Number 4, 2016
- **Volume 51:**
  - Number 1, 2016
  - Number 2, 2016
  - Number 3, 2016
  - Number 4, 2016
- **Volume 52:**
  - Number 1, 2016
  - Number 2, 2016
  - Number 3, 2016
  - Number 4, 2016
  - Supplement 1, 2016
- **Volume 53:**
  - Number 1, 2016
  - Number 2, 2016
  - Number 3, 2016
  - Number 4, 2016
  - Supplement 1, 2016
- **Volume 54:**
  - Number 1, 2016
  - Number 2, 2016
  - Number 3, 2016
  - Number 4, 2016

2017
- **Volume 55:**
  - Number 1, 2017
  - Number 2, 2017
  - Number 3, 2017
  - Number 4, 2017
- **Volume 56:**
  - Number 1, 2017
  - Number 2, 2017
  - Number 3, 2017
  - Number 4, 2017
- **Volume 57:**
  - Number 1, 2017
  - Number 2, 2017
  - Number 3, 2017
  - Number 4, 2017
- **Volume 58:**
  - Number 1, 2017
  - Number 2, 2017
  - Number 3, 2017
  - Number 4, 2017
- **Volume 59:**
  - Number 1, 2017
  - Number 2, 2017
  - Number 3, 2017
  - Number 4, 2017
- **Volume 60:**
  - Number 1, 2017
  - Number 2, 2017
  - Number 3, 2017
  - Number 4, 2017
Recent special issues:

- Subjective Cognitive Impairment (Guest Editor: Andrea Tales, Frank Jessen, Christopher Butler, Gordon Wilcock, Judith Phillips, Tony Bayer)
- Volume 44:3 - Our 200th Issue!
- Mini-Forum "The Assessment of Dementia by the Latent Variable 'δ'" (Guest Editor: Donald Royall)
- Proceedings of the XI Convegno Nazionale Meeting (SINDEM 2016)
- Proceedings of the 2nd International Meeting of the Milan Center for Neuroscience (Neuromi 2016)

Upcoming:

- Epidemiological Aspects of Subjective Cognitive Impairment and Mild Cognitive Impairment: Population-Based Data (Guest Editor: Roberto Monastero)
- Neurotransmitters and Alzheimer’s Disease (Guest Editor: P. Hemachandra Reddy)
- Sphingolipids in Neurodegenerative Diseases (Guest Editors: Michelle Mielke and Pilar Martinez)
- Molecular Pathways in Aging and Neurodegeneration: Mechanisms and Therapeutics (Guest Editors: K.S. Jagannatha Rao, George Perry, YZ Zhu, Muralidhar Hegde, Thomas von Zglinicki, Miguel Perez-Pinzon)
Ethics Review as a Catalyst for Progress  Rosen AC et al.
Is There More to Subjective Cognitive Impairment than Meets the Eye? A Perspective  Tales A et al.
Is There More to Subjective Cognitive Impairment than Meets the Eye? Obligations and Opportunities  Rosen AC
Is There More to Subjective Cognitive Impairment than Meets the Eye? Raising Awareness  Tales A et al.
Can We Do Better? Researchers’ Experiences with Ethical Review Boards on Projects with Later Life as a Focus  Pachana NA et al.
Investigators’ Perceptions of Research Oversight: Are Regulators Really Undermining Autonomy?  Lingler JH
Psychometric Properties of a Decisional Capacity Screening Tool for Individuals Contemplating Participation in Alzheimer’s Disease Research  Seaman JB et al.
Different Diagnosis, Shared Vulnerabilities: The Value of Cross Disorder Validation of Capacity to Consent  Rosen AC and Weitlauf JC
False Positives, Outliers, and Other Considerations in Decisional Capacity Screening for Research Consent  Lingler JH et al.
Complementary and alternative medicine in the context of earlier diagnoses of Alzheimer’s disease: Preparing the ethical response  Racine E et al.
The Online Environment: A Key Variable in the Ethical Response to Complementary and Alternative Medicine for Alzheimer’s Disease  Robillard JM
Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment  Lingler JH et al.
Do Chinese Researchers Conduct Ethical Research and Use Ethics Committee Review in Clinical Trials of Anti-Dementia Drugs? An Analysis of Biomedical Publications Originating from China  Zeng L et al.
Approaches to Increasing Ethical Compliance in China with Drug Trial Standards of Practice  Rosenberg J
A Population Perspective on Ethical Compliance with Drug Trial Standards of Practice  Wang N et al.
Median turnaround time in 2015: 27 days
Average turnaround time (5-year period): 25.8 days
Top 10 journals citing JAD:

- PLOS ONE
- NEUROBIOL AGING
- CURR ALZHEIMER RES
- ALZHEIMERS DEMENT
- FRONT AGING NEUROSCI
- NEUROSCIENCE
- MOL NEUROBIOL
- SCI REP-UK
- NEUROBIOL DIS
- FRONT NEUROL

From JCR 2015
Top 10 cited articles all time:

1. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in AD - is this type 3 diabetes? de la Monte SM et al. (2005), Times Cited: 576
2. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways Cogswell JP et al. (2008), Times Cited: 321
3. Insulin and insulin-like growth factor expression and function deteriorate with progression of AD: Link to brain reductions in acetylcholine de la Monte SM et al. (2005), Times Cited: 264
6. Curcumin interaction with copper and iron suggests one possible mechanism of action in AD animal models Baum L and Ng A (2004), Times Cited: 219
7. Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic de la Monte SM et al. (2006), Times Cited: 213
8. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults Craft S et al. (2008), Times Cited: 190
10. PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses Bush AI et al. (2010), Times Cited: 170
Top 10 cited articles published in 2015:

1. **Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer’s Disease** Wischik CM et al. Times Cited: 30
2. **Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer’s Disease Dementia** Craft S et al. Times Cited: 27
3. **A Phase II Trial of Tideglusib in Alzheimer’s Disease** Del Ser T et al. Times Cited: 26
4. **2003-2013: A Decade of Body Mass Index, Alzheimer’s Disease, and Dementia** Gustafson DR et al. Times Cited: 21
5. **Brain Changes in Alzheimer’s Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor** Eriksdotter M et al. Times Cited: 15
8. **Air Pollution and Children: Neural and Tight Junction Antibodies and Combustion Metals, the Role of Barrier Breakdown and Brain Immunity in Neurodegeneration** Calderon-Garciduenas L et al. Times Cited: 13
10. **Prodromal Alzheimer’s Disease Presenting as Cerebral Amyloid Angiopathy-Related Inflammation with Spontaneous Amyloid-Related Imaging Abnormalities and High Cerebrospinal Fluid Anti-A beta Autoantibodies** Boncoraglio GB et al. Times Cited: 11
Top 10 viewed articles in 2015:

1. Altered Sense of Humor in Dementia  Warren J et al.
2. Stress, Meditation, and Alzheimer’s Disease Prevention: Where The Evidence Stands  Khalsa DS
3. Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer’s Disease Dementia  Craft S et al.
5. Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology  Rosenberger AFN et al.
7. Chronic Aluminum Intake Causes Alzheimer’s Disease: Applying Sir Austin Bradford Hill’s Causality Criteria  Walton JR
8. Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging  Raji CA et al.
10. Aluminum Involvement in the Progression of Alzheimer’s Disease  Walton JR
Editorial board policy:

- Terms of new Associate Editors will begin January 1st of the following calendar year.

- Terms can be extended by one year by performing Acts of Service with a limit of two extensions in any given year. Once this limit has been reached, additional acts of service will be applied to the goal of Senior editorship for that year.

- To elevate to Senior Editor status, an Associate Editor must complete five (5) Acts of Service during a one-year period. Guest editing a Special Issue automatically qualifies the Associate Editor for Senior editorship in the subsequent year.

- Senior Editors are responsible for soliciting and handling review articles and, to maintain status as Senior Editor, must solicit at least two review articles per year as part of their five (5) Acts of Service.

- 75% of corresponding authors accept the Associate Editor invitation.
Location of Editorial Board

- Europe, 45.8%
- North America, 30.4%
- Asia/Pacific, 20.6%
- South America, 1.6%
- Middle East, 1.3%
- Africa, 0.3%

Top Reviewers in 2015
Jesus Avila, Amos Korczyn, Giulio Pasinetti, Thomas Shea, Massimo Tabaton, Wenzhang Wang

Editors with the most Acts-of-Service in 2015
Daniela Galimberti (10), Carlo Abbate (8), Jason Brandt (8), Francesco Panza (8)
Policies

Author Instructions:
- Policy on the Use of Animals
- Policy on the Use of Human Subjects
- Policy on Ethics
- Financial Disclosure
- Compliance with Major Funding Agencies (including PubMed Central and NIH Public Access)

- Green Open Access Publishing in JAD (Self-Archiving)
Authors may self-archive and post the final manuscript version on their own institution, company or funding agency repositories immediately upon acceptance. Authors that are funded by the NIH, Research Councils UK (RCUK) and Wellcome Trust are welcome to deposit their final manuscript version to PubMed Central with no embargo.

- Gold Open Access Publishing in JAD (Open Access Option EUR900 / $1250)
This option allows authors the choice of paying a fee to make their article publicly available on the journal’s website immediately upon publication. Open Access articles will be deposited directly into PubMed Central by IOS Press.

JAD is compliant to mandates by NIH, RCUK and Wellcome Trust.
Optional Open Access:

<table>
<thead>
<tr>
<th>Year</th>
<th>Open Access</th>
<th>Total Articles</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>46</td>
<td>452</td>
<td>10%</td>
</tr>
<tr>
<td>2011</td>
<td>63</td>
<td>375</td>
<td>17%*</td>
</tr>
<tr>
<td>2012</td>
<td>48</td>
<td>465</td>
<td>10%</td>
</tr>
<tr>
<td>2013</td>
<td>30</td>
<td>457</td>
<td>7%</td>
</tr>
<tr>
<td>2014</td>
<td>55</td>
<td>599</td>
<td>9%</td>
</tr>
<tr>
<td>2015</td>
<td>57</td>
<td>629</td>
<td>9%</td>
</tr>
</tbody>
</table>

*2011: outlier due to 2 OA sponsored special issues
Vol. 1. *Handbook of Animal models in Alzheimer’s Disease*  
G. Casadesus (Ed.), 2011

Vol. 2. *Handbook of Imaging The Alzheimer Brain*  

Vol. 3. *Alzheimer’s Disease: Advances for a New Century*  
G. Perry, X. Zhu, M.A. Smith†, A. Sorensen, J. Avila (Eds.), 2013

Vol. 4. *Handbook of Depression in Alzheimer’s Disease*  
G.S. Smith (Ed.), 2015

Vol. 5. *Handbook of Infectious Origin of Alzheimer’s Disease*  
J. Miklossy (Ed.), 2016  COMING FALL 2016
Newest book:

**Handbook of Depression in Alzheimer’s Disease**

Editor: G.S. Smith  
July 2015, 396 pp., hardcover  
Volume 4, Advances in Alzheimer’s Disease  
ISBN 978-1-61499-541-8 (print)  
Price: US$155 / €135 / £115

Conference discount: 25%  
JAD Editor discount: 35%  
Author discount: 50%  
(contact r.holst@iospress.nl to order book with discount)
Alzheimer Award Winner 2016

The Journal of Alzheimer’s Disease (JAD) is pleased to announce that Mark W. Bondi, PhD, ABPP/CN, Professor of Psychiatry at UC San Diego and Director of the Neuropsychological Assessment Unit at the VA San Diego Healthcare System, has been chosen as the recipient of the 2010 Alzheimer Award presented by the Journal in recognition of his outstanding work on the development of a novel and promising method of staging preclinical Alzheimer’s disease (AD) based on number of abnormal biomarkers that is predictive of progression to mild cognitive impairment (MCI) and AD.

The winning paper is “Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer’s Disease” (J Alzheimer’s Dis 47, 231-242, 2015), which is freely available to all readers.

“By clearly defining subtle cognitive decline via sensitive and reliable neuropsychological test scores, and by exploring timetables of biomarker and cognitive changes, we hope to improve diagnostic precision of preclinical AD and sharpen our ability to identify early signs associated with different neurobiological pathways to the diagnosis of AD,” explained Dr. Bondi. “I would like to thank the article’s lead author, Dr. Emily Edwards, and the entire research team, whose work helped achieve these significant results. And I would like to thank the editors of the journal, who selected our paper among the hundreds published by the journal in 2015.”

Each year, the Associate Editors of the journal select the best article from the previous year’s volumes. The awardee is presented the Alzheimer Medal, a 3” bronze medal with the likeness of Alois Alzheimer and a cash prize of $500. This annual award is made possible by support from the Alzheimer’s Research & Prevention Foundation and IOS Press, publisher of JAD.

“We are pleased to support JAD in presenting this well-deserved award,” Dr. Bondi’s work concedes with ours and we hope it will highlight the importance of early, non-pharmacological interventions to prevent AD,” remarked Chandra Singh Khalsa, MD, PresidentMedical Director of the Alzheimer’s Research and Prevention Foundation and Clinical Associate Professor, Department of General Internal Medicine, Geriatrics and Integrative Medicine, University of New Mexico Health Sciences Center.

Volume 53, Number 3 / 2016 Available Online

Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer’s Disease - Openly Available

Avanish, Gary W.

Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPsw/Ps1ΔE9 Transgenic Mouse Models of Alzheimer’s Disease - Openly Available

Alcalá, José Antonio | Samoleva, Natalia | Lico, Maria | Pérez-Ortíz, Virginia | Fanlo, Nieves | Pancene-Lucas, Maria | Cejudo, Samuel | Pedra, Pedro | Saras, Manuel

Non-Fibrillar Oligomeric Amyloid-β within Synapses

Procaccioni, Giuseppe | Knott, Robert M | Vogman, Susan | Henstridge, Christopher M | Hermann, Aligail G | Colos-Cadieu, Math | Lleo, Albert | Koy, Kevin P | Vailt, Nobessa | Soderman, Roy | Walsh, Dominic M | Hynan, Bradley T | Spies-Jones, Tara L

Uncovering the Neural Basis of Cognitive and Affective Empathy Deficits in Alzheimer’s Disease and the Behavioral-Variant of Frontotemporal Dementia

Demody, Nadine | Wong, Stephanie | Ahmed, Rebekah | Miguel, Oliver | Hordes, John R | Iroh, Murenni

Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer’s Disease

Ooboshi, Yumi | Kikuchi, Miwako | Terada, Takahiro | Yoshikawa, Etsuji | Sumi, Tomoyasu | Ouchi, Yasuimi

More Contents

Volume 53, Number 4 / 2016 Available Online

A Bacterial Component of Alzheimer’s-Typed Demantia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammation Shedding to Disease

Purvis, Ethenisa | Easter, Janet | Kiel, Douglas B.

Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer’s Disease

Adile, Rejyfald C | Adile, Chidusak A.
Media coverage:

Drinking coffee regularly can reduce the risk of Alzheimer's 'by boosting caffeine levels in the blood'

- Volunteers who remained healthy had twice as much caffeine circulating than those who progressed to the early stages of dementia
- First direct evidence that coffee intake is associated with a reduced risk, or delayed onset, of dementia

By PAT HAGAN FOR MAILONLINE

Change in sense of humour 'a sign of impending dementia'

An increasingly warped sense of humour could be an early warning sign of impending dementia, say UK experts.

The University College London study involved patients with frontotemporal dementia, with the results appearing in the Journal of Alzheimer's Disease.

Questionnaires from the friends and family of 44 patients revealed many had noticed a change in humour years before the dementia had been diagnosed.

This included laughing inappropriately at tragic events.
Top 10 JAD Press Releases 2015

Coffee Consumption Habits Impact the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging

Changes in Humour May Be an Early Sign of Dementia

Surprising Finding Provides More Support for Alzheimer’s Being an Autoimmune Disease

Green Tea Extract and Exercise Hinder Progress of Alzheimer’s Disease in Mice

First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease

Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer’s Dementia

Study Disproves Link Between Lyme Disease and Alzheimer’s

Adverse Side Effects of Intranasal Detemir Insulin in the SNIFF Trial

Running and Walking may Lower Alzheimer’s Disease Risk

A virtual reality brain training game can detect mild cognitive impairment, a condition that often predates Alzheimer’s disease
“Dietary Supplementation of Walnuts Improves Memory Deficits and Learning Skills in Transgenic Mouse Model of Alzheimer’s Disease” Chauhan et al.

Secured Coverage (48,858,838 total print, online & broadcast impressions):

Print Coverage:
• St. Louis Post-Dispatch
• The Columbus Dispatch
• The Times Picayune
• Albuquerque Journal
• Newsday
• The Boston Globe
• The Commercial Appeal
• The News Tribune
• Etc.

Radio:
• SmartBrief for Nutritionists
• ABC News Radio Online
• KRVN River Radio Online
• KTIC Rural Radio Online
• WAPI Radio Online
• KMBZ Kansas City Radio
• KIXI Radio Online
• KLIQ Radio Online

Webpages Coverage:
• Columbus News Team Online
• Messenger-Inquirer
• The Financial Express
• Help Me Out Doc
• Alzheimer’s News Today
• The Columbus Dispatch
• Express UK Online
• The Boston Globe Online
• Express UK Online
• The Boston Globe Online

TV:
• KTRS-AM
• KVNU-AM (ABC)
• KSWB-SD Fox5
• KOAT-ABQ ABC Action 7 News
• WTXF – PHI Fox 29 News at Noon
• WWSB ABC 7 News at Noon, Tampa, FL
• WXIX – TV Channel 19, Cincinnati, OH

Press Release Pick-Up:
• The press release has been picked-up by 219 websites, with a potential audience of 70,818,000.

Social Mentions:
• 499 Twitter mentions
• 301 Facebook mentions
• 18 blog posts
• 1 forum post
• Largely driven by the Huffington Post and Washington Post articles.
Improved website:

In the delayed-match-to-sample task, mild cognitive impairment patients (MCI) showed reduced repetition-driven suppression in the occipital brain regions relative to normal controls (NC). Activation is in red and deactivation is in blue. From Yu et al., JAD S3(2).
Website Features:

**Blog**
- Invite Experts to write Blogs on relevant, topical issues or urgent questions
- Community interaction
- Latest Blogs by Ruth Itzhaki, Giulio Pasinetti and Paula Moreira

**Editor’s Pick**
- A recommendation of new high-profile articles as selected by the Editor-in-Chief

**Most Popular Articles**
- See what your community is most interested in reading today

**AD Funding Analyzer**
- A helpful tool to look for funding trends and to see which investigators in which countries have been the most successful in obtaining funding for a given area of AD research

**In Development**
- The JAD community have selected the 50 “game-changing” articles 2006-2015
- Eligible articles were not necessarily most highly cited: e.g. no reviews; must impart significant new knowledge.
- Target production of a special issue & e-Book w/ moderated community discussion & reviews

**Meta-objectives**
- Draw readers to the new JAD web platform
- Help make it a place they will visit every week
- Bring ten years of key AD research developments together in one place and discuss in community
The Journal of Alzheimer’s Disease

2016

ALZHEIMER AWARD

Mark Bondi, Ph.D.

for his article

“Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer’s Disease”


Sponsored by:

IOS Press
Thank you for your attention

Any questions?

editorial@j-alz.com